Welcome to our dedicated page for Tectonic Therapeutic SEC filings (Ticker: TECX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tectonic Therapeutic, Inc. (NASDAQ: TECX) SEC filings page brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tectonic is a clinical-stage biotechnology company focused on GPCR-targeted biologic medicines, and its filings provide structured insight into financial results, clinical development updates and corporate events.
Investors can use this page to access Form 10‑Q and Form 10‑K reports, which contain detailed discussions of Tectonic’s research and development activities, risk factors, and financial statements. For a company advancing programs such as TX45 in Group 2 pulmonary hypertension and PH‑ILD, and TX2100 for Hereditary Hemorrhagic Telangiectasia, these periodic reports explain how clinical trial progress and pipeline strategy relate to operating expenses and liquidity.
The page also surfaces Form 8‑K current reports, where Tectonic discloses material events such as quarterly financial results, positive topline clinical data, updated corporate presentations, and other significant announcements. These filings often reference attached press releases and slide decks that elaborate on trial designs, endpoints, and topline outcomes.
In addition, users can review Section 16 filings such as Form 4, which report changes in beneficial ownership by directors, officers, and other insiders, as well as proxy materials that discuss governance and executive compensation. Stock Titan’s platform layers AI-powered summaries on top of these documents to highlight key points, explain technical language, and help readers quickly understand the implications of lengthy filings without replacing the underlying source documents.
Together, the TECX SEC filings and AI summaries give a structured view of how Tectonic communicates its financial condition, clinical-stage risks, and strategic focus on GPCR-targeted biologics to regulators and investors.
Tectonic Therapeutic, Inc. reported that Chief Financial Officer Daniel Lochner received a grant of performance stock options covering 7,500 shares of common stock. The options have an exercise price of $16.80 per share, expire on June 19, 2034, and are fully vested and immediately exercisable as of June 1, 2026. The 7,500 shares represent 50% of a larger performance-based award already earned after the board certified certain performance goals, while the remaining 50% will be earned only if additional performance criteria are met.
Tectonic Therapeutic, Inc. reported results from its 2026 Annual Meeting and a key clinical milestone. Stockholders elected Timothy A. Springer and Stefan Vitorovic as Class II directors, with up to 13.9 million votes for each candidate, and ratified Deloitte & Touche LLP as independent auditor with 17,225,948 votes for and minimal opposition. Stockholders also approved, on an advisory basis, executive compensation with 14,292,497 votes in favor.
The company announced completion of enrollment in APEX, its 24‑week, global Phase 2 trial of TX45 in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH‑HFpEF). APEX enrolled 191 patients across 14 countries, including 137 with the more severe combined pre‑ and post‑capillary pulmonary hypertension (CpcPH) and pulmonary vascular resistance above 3 Wood Units. Tectonic plans to report topline APEX results in early Q1 2027.
Tectonic Therapeutic, Inc. reported that director and 10% owner Timothy A. Springer received a grant of stock options covering 10,200 shares of common stock. The options have an exercise price of $28.56 per share and expire on June 8, 2036.
The award vests in full on the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a defined change in control, provided he continues to serve the company through that date.
Tectonic Therapeutic, Inc. director Praveen P. Tipirneni received a grant of stock options covering 10,200 shares of common stock at an exercise price of $28.56 per share. These options were awarded as a compensation grant, not an open-market purchase or sale.
The options vest in full on the earliest of June 9, 2027, the company’s 2027 annual meeting of stockholders, or a qualifying change in control, as long as the director continues providing service through that date. After this grant, the reported derivative holdings in this award total 10,200 options.
Tectonic Therapeutic, Inc. director Phillip B. Donenberg reported a compensation-related equity award. He received a stock option to acquire 10,200 shares of common stock at an exercise price of $28.56 per share, giving him the right, but not the obligation, to buy company stock at that price.
The option vests in full on the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a qualifying change in control, as long as he continues serving the company through that date. Following this grant, he holds 10,200 stock options directly, with an expiration date in 2036.
Tectonic Therapeutic, Inc. director Stefan Vitorovic received a grant of stock options covering 10,200 shares of common stock. The options have an exercise price of $28.56 per share and expire on June 8, 2036, bringing his option holdings to 10,200 shares.
According to the terms, the award vests in full on the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a qualifying change in control, in each case only if he continues providing service to the company through that date.
Tectonic Therapeutic, Inc. reported that director Jessica Caroline Chutter received a grant of stock options covering 20,400 shares of common stock. The options have an exercise price of $29.10 per share and expire on June 7, 2036.
According to the vesting terms, one-third of the option shares will vest on June 8, 2027, with the remaining shares vesting in 24 equal monthly installments after that date, subject to Ms. Chutter’s continued service with the company. Following this grant, she holds 20,400 stock options directly.
Tectonic Therapeutic, Inc. reported that Jessica Caroline Chutter has become a reporting person as a director on a Form 3. This filing is an initial statement of beneficial ownership and does not list any stock holdings or report any buy, sell, or option exercise transactions.
Tectonic Therapeutic, Inc. reported first quarter 2026 results and updated progress on its clinical pipeline. The company ended March 31, 2026 with cash and cash equivalents of $236.9 million, which it expects will fund operations into Q4 2028, including Phase 2 readouts for TX45 in PH-HFpEF and PH-ILD and continued development of TX2100 for HHT.
Research and development expenses rose to $20.9 million from $13.0 million a year earlier, and general and administrative expenses increased to $6.4 million from $5.3 million. Net loss widened to $25.2 million from $15.9 million, reflecting heavier investment in clinical trials and personnel.
Clinically, TX45’s APEX Phase 2 trial in PH-HFpEF is ongoing with topline data expected in late Q4 2026 or early Q1 2027, while the ALPINE Phase 2 trial in PH-ILD has begun enrollment. TX2100 advanced into a Phase 1a trial in healthy volunteers, with topline data expected by the end of Q3 2026 and a Phase 2 HHT study planned for early 2027.
Tectonic Therapeutic, Inc. reported a larger quarterly loss as it ramped up clinical development. For the three months ended March 31, 2026, net loss was $25.2 million compared with $15.9 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $20.9 million from $13.0 million, largely from CRO and CDMO costs for TX45 Phase 2 trials and a bigger R&D team. General and administrative expenses increased to $6.4 million from $5.3 million, reflecting higher stock-based compensation and staffing.
The company ended the quarter with $236.9 million in cash and cash equivalents and used $18.4 million in operating cash flow. Management believes this cash will fund operations for at least 12 months. Tectonic advanced its pipeline, including the APEX Phase 2 trial of TX45 in PH-HFpEF, a new Phase 2 trial in PH-ILD, and a Phase 1a healthy volunteer trial of TX2100 for HHT.